Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $58.8 million.

  • C4 Therapeutics' Cash & Equivalents fell 140.82% to $58.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.8 million, marking a year-over-year decrease of 140.82%. This contributed to the annual value of $55.5 million for FY2024, which is 5615.85% down from last year.
  • C4 Therapeutics' Cash & Equivalents amounted to $58.8 million in Q3 2025, which was down 140.82% from $78.2 million recorded in Q2 2025.
  • C4 Therapeutics' 5-year Cash & Equivalents high stood at $281.1 million for Q2 2021, and its period low was $29.8 million during Q4 2022.
  • For the 5-year period, C4 Therapeutics' Cash & Equivalents averaged around $81.3 million, with its median value being $59.6 million (2024).
  • Per our database at Business Quant, C4 Therapeutics' Cash & Equivalents tumbled by 7962.06% in 2022 and then surged by 32545.54% in 2023.
  • C4 Therapeutics' Cash & Equivalents (Quarter) stood at $76.1 million in 2021, then plummeted by 60.91% to $29.8 million in 2022, then skyrocketed by 325.46% to $126.6 million in 2023, then plummeted by 56.16% to $55.5 million in 2024, then grew by 5.96% to $58.8 million in 2025.
  • Its last three reported values are $58.8 million in Q3 2025, $78.2 million for Q2 2025, and $51.3 million during Q1 2025.